Beatrice Gini

University of California, San Francisco — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

23h-index4.4kcitations83works13.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PI3K/AKT/mTOR signaling in cancer(18), RNA modifications and cancer(13), Cancer Genomics and Diagnostics(11), Lung Cancer Treatments and Mutations(10), Microtubule and mitosis dynamics(10)

Publications83 total

Acquired resistance in cancer: towards targeted therapeutic strategies
Nature reviews. Cancer·2025· 37 citedOpen Access
Actionable biological programs to enhance EGFR-targeted therapy response unveiled by single-cell lineage tracing in clinically relevant lung cancer models
2025Open Access
CDK4 or CDK6 upregulation induces DNA replication stress and genomic instability to cause EGFR targeted therapy resistance in lung cancer
2024· 3 citedOpen Access
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance
Nature Genetics·2023· 76 citedOpen Access
Supplementary Methods, Figures 1-9 from An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway
2023Open Access
Interview with Dr. Mischel from Oncogenic EGFR Signaling Activates an mTORC2–NF-κB Pathway That Promotes Chemotherapy Resistance
2023Open Access
Interview with Dr. Mischel from Oncogenic EGFR Signaling Activates an mTORC2–NF-κB Pathway That Promotes Chemotherapy Resistance
2023Open Access
Supplementary Methods, Figures 1-9 from An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway
2023Open Access
Supplementary Figures 1-13, Tables 1-2 from Oncogenic EGFR Signaling Activates an mTORC2–NF-κB Pathway That Promotes Chemotherapy Resistance
2023Open Access
Data from Oncogenic EGFR Signaling Activates an mTORC2–NF-κB Pathway That Promotes Chemotherapy Resistance
2023Open Access
Supplementary Figures 1-13, Tables 1-2 from Oncogenic EGFR Signaling Activates an mTORC2–NF-κB Pathway That Promotes Chemotherapy Resistance
2023Open Access
Data from An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway
2023Open Access
Data from Oncogenic EGFR Signaling Activates an mTORC2–NF-κB Pathway That Promotes Chemotherapy Resistance
2023Open Access
Supplementary Material from Oncogenic EGFR Signaling Activates an mTORC2–NF-κB Pathway That Promotes Chemotherapy Resistance
2023Open Access
Data from An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway
2023Open Access
Supplementary Material from Oncogenic EGFR Signaling Activates an mTORC2–NF-κB Pathway That Promotes Chemotherapy Resistance
2023Open Access
Supplementary Figure 4 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
2023Open Access
Supplementary Figure 7 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
2023Open Access
Supplementary Figure 3 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
2023Open Access
Supplementary Figure 2 from The mTOR Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-Activated Glioblastomas
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Paul S. Mischel(23), Timothy F. Cloughesy(18), Bruno Bonetti(17), Webster K. Cavenee(16), Kenta Masui(15), David A. Nathanson(14), David Akhavan(14), Ivan Babić(14), Deliang Guo(13), Huijun Yang(12), Yuchao Gu(11), Frank B. Furnari(10), Tomoo Matsutani(10), Genaro R. Villa(10), James R. Heath(9), Shiro Ikegami(9), Ciro Zanca(9), Trever G. Bivona(8), Rajesh Chopra(8), Alvaro Assuncao(8)